Dxcover Limited
11:00 AM - 11:15 AM (EDT), Wednesday, June 7, 2023 ・ Session Room 104A
o Dxcover is a clinical stage liquid biopsy company developing tests for the early detection of multiple cancers, when treatment has a better chance to impact outcomes. The company has pioneered the early detection and identification of cancer by employing infrared spectroscopy of circulating pan-omic biomarkers. The company has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers. Dxcover is based in Scotland, United Kingdom and is establishing operations in the USA.
While most liquid biopsy companies focus exclusively on detecting tumor DNA in the bloodstream, which only appears once the cancer has progressed, Dxcover pioneered a new approach of detection by employing attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy on circulating pan-omic biomarkers, which allows them to identify cancer at its earliest stages when the patient has the best chance of improved survival and quality of life.
While most liquid biopsy companies focus exclusively on detecting tumor DNA in the bloodstream, which only appears once the cancer has progressed, Dxcover pioneered a new approach of detection by employing attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy on circulating pan-omic biomarkers, which allows them to identify cancer at its earliest stages when the patient has the best chance of improved survival and quality of life.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
2016
Main Therapeutic Focus:
Diagnostics
Lead Product in Development:
Multi-Cancer Early Detection Liquid Biopsy
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
